Study: RNA analysis shows most SARS-Cov2 variants rarely persist through secondary transmission

A large team of researchers affiliated with a host of institutions across the U.K. has found that most SARS-CoV-2 variants rarely persist through secondary transmissions. In their paper published in the journal Science, the group the RNA sequencing of nearly 1,400 nasal swabs from patients between March and June of last year, and what they found by doing so.

As the global pandemic has progressed, attention has turned to variants of the virus that infect people with COVID-19. A growing fear is that some of the new variants will prove to be immune to the vaccines that are being given to combat the original form of the virus, setting off a whole new pandemic. This new effort was conducted late last year, before most of the new variants had made their way into news headlines. The researchers sought to better understand the danger posed by these SARS-CoV-2 variants. More specifically, they wanted to know more about how frequently they arise and how easily they can spread.

The work by the team involved obtaining 1,313 nasal swabs collected from infected people in the U.K. between March and June of last year—most of whom exhibited symptoms of COVID-19. Each of the samples was then subjected to RNA sequencing to identify variants.

The researchers found that most of the infected people had only one or two variants, most of which were not able to survive transmission to other people. They did find that a few of those infected had variants that could survive transmission, though they found very few instances of them transmitted between households.

The researchers suggest their findings indicate that, at least during early infection, mutations that are able to survive attacks by antibodies are quite rare. That being said, they did find evidence of variants whose mutations gave them a better chance of surviving an immune response. Such mutations, they note, would be more likely to spread as vaccine use becomes more widespread. They suggest that monitoring will have to be stepped up to quickly identify variants that may not be weakened by current vaccines.